Compare Recursion Pharmaceuticals Inc (RXRX) vs Workday Inc (WDAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Workday Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $4.06 (market cap $2.14B), while Workday Inc trades at $189.54 (market cap $45.26B). The key difference: Workday Inc is far larger — about 21.1× Recursion Pharmaceuticals Inc's market cap, and Workday Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Workday Inc for 38 Days on average.
| RXRX | WDAY | |
|---|---|---|
Market Cap | $2.14B | $45.26B |
Volume | 30,789,535 | 2,342,190 |
Sector | Health | Technology |
52-Week High | $6.79 | $245.67 |
52-Week Low | $2.84 | $112.55 |
Typical Hold Time | 22 Days | 38 Days |
Enterprise Value | $1.66B | $45.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Workday (WDAY) trades at $184.26, down 1.23% on the day amid a broader tech selloff, with a bearish technical signal. The company shows strong revenue growth, reaching $8.45B in 2025, and has consistently beaten earnings estimates. Recent strategic moves include AI product launches and a 2.5% headcount reduction aimed at efficiency. Analyst consensus is bullish with a $202.92 price target, but negative net cash flow and high valuation ratios present risks.
The outlook for WDAY is mixed; strong fundamentals and AI integration offer growth potential, but high P/E of 38.25 and recent layoffs signal execution risks. Investors should weigh robust analyst support against valuation concerns and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Workday Inc
Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.
Read more on WDAY →
